Adjuvant therapy in renal cell carcinoma-past, present, and future.
about
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementInhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential.Renal cell carcinoma.Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma.Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testingIL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.Increased expression of metastasis-associated in colon cancer-1 in renal cell carcinoma is associated with poor prognosis.PD-L1 expression in papillary renal cell carcinomaNrdp1-mediated degradation of BRUCE decreases cell viability and induces apoptosis in human 786-O renal cell carcinoma cellsOrgan Atrophy Induced by Sorafenib and Sunitinib - Quantitative Computed Tomography (CT) Evaluation of the Pancreas, Thyroid Gland and Spleen.Epigenetic therapy in urologic cancers: an update on clinical trials.Effects of obesity on immune responses to renal tumors.The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinomaElevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma.Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?Treatment of renal cell carcinoma: Current status and future directions.Risk factors for locoregional relapse after radical nephrectomy.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.Evaluation of gene expression level of CDC5L and MACC1 in poor prognosis and progression of osteosarcomaRenal cancer: new models and approach for personalizing therapyAdjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysisSorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot StudymiRNA-21 and miRNA-223 expression signature as a predictor for lymph node metastasis, distant metastasis and survival in kidney renal clear cell carcinomaIs there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts
P2860
Q26801279-DD3CD696-CD96-4790-8789-A9FA2C0C8916Q27304863-5EE1D37A-B5BA-4BE8-877D-3D255CE8A365Q30235364-33D8B37F-8061-4C27-8141-0352D0F68351Q34306503-375F96F4-A58A-42A0-A78B-DC8E88276323Q34371366-D2827778-4572-4BC4-BC16-19566A984D81Q35041892-D28FFD51-D9E6-45A6-8C38-2CC88D764637Q35274936-0C9217F7-70DA-48E9-8D97-F38B4585C25FQ35643696-F4201A7B-5563-4631-9F92-5866D6329BD5Q35741048-9ED8FB75-50CF-4ADF-B6DD-0EB16E6257A2Q36249417-55C62BB4-ADAB-4E36-9DFD-E1E28212B3D4Q37108323-D7349F47-3DE4-44CB-B520-A84CA3A01B51Q37456989-4D455D04-140A-41A0-8E42-D72BC3461442Q37707110-6B64B692-A47A-482A-AC86-BA4441FDC7E9Q38212548-84DD5D52-5BA3-406C-8353-A2A2964FFD47Q38769269-5C720540-0099-42C0-A4A0-39A2212FBE8FQ39204706-C08221BF-13E6-46A2-812F-33C48AEB030FQ41447434-BE6F12CA-102B-4F36-AC4D-537DC28BF8A4Q42722494-3C64D6EE-F5EE-4C97-AAC7-F88F98AC5207Q47397616-C4B690CC-4BFB-4E57-89C9-F89FD42B19FBQ47726014-AA2E8482-E1B6-4D89-974D-0B00596B5451Q48166055-5B812D14-3C08-4724-9A9F-46B06D88D049Q48368561-9893EDA0-4095-493A-AF1E-1422E6E93548Q50119482-A2A9921D-0C82-41E3-B95B-5DC3C58D98CAQ56486862-88CB9F29-EBFF-4FF8-81FF-4445A7944777Q57160714-81EBF5AA-E9D8-429E-8FA5-49592EA2D6D9Q57825312-575905FF-4DFD-45D0-852B-2AAF9393703AQ58544252-7840EDC8-D658-42AB-A30F-7C1D2581DA1CQ58555671-D290BED5-5AE9-4494-9D76-AC98D806F27FQ59126184-FD2D35FB-8A8D-4078-8F7B-C5BF9D049DD2
P2860
Adjuvant therapy in renal cell carcinoma-past, present, and future.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@en
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@nl
type
label
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@en
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@nl
prefLabel
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@en
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@nl
P2093
P2860
P921
P1433
P1476
Adjuvant therapy in renal cell carcinoma-past, present, and future.
@en
P2093
Kamarul Zaki
Peter Mulders
Sarah J Welsh
Tobias Janowitz
P2860
P304
P356
10.1053/J.SEMINONCOL.2013.05.004
P5008
P577
2013-08-01T00:00:00Z